SCHEMBL10072130

SCHEMBL10072130

CCCCCCCCCCCCCCCOCC(CO)OCCCC

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.61
LPAR1 Q92633 7/20 0.58
LPAR3 Q9UBY5 7/20 0.58
LPAR2 Q9HBW0 4/20 0.58
ALDH1A1 P00352 1/20 0.53
CNR1 P21554 1/20 0.53
CNR2 P34972 1/20 0.53
TLR2 O60603 2/20 0.50
HTT P42858 2/20 0.50
DNM1 Q05193 1/20 0.50
MEN1 O00255 1/20 0.48
THRB P10828 1/20 0.48
KMT2A Q03164 1/20 0.48
MAPT P10636 1/20 0.48
LPAR6 P43657 3/20 0.47
LPAR4 Q99677 3/20 0.47
LPAR5 Q9H1C0 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10071648 1.00 USP2 (0.61) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7060157 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL10561321 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL103054 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL2417250 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL25266425 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7063456 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL15016340 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7063486 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7058701 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334235-B2 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging PHENOMENOME DISCOVERIES INC. (CA) 2016-05-10 US disclosed
US-20120035250-A1 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHENOMENOME DISCOVERIES INC. (CA) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035250-A1 PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING PHOSPHO1, SGMS2, MBOAT1 USP2 3903/4885LPAR1 111/4885LPAR3 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.